These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6470957)

  • 1. Dissolution studies of some sustained-release theophylline dosage forms.
    Simons KJ; Simons FE; Plett KD; Scerbo C
    J Pharm Sci; 1984 Jul; 73(7):939-42. PubMed ID: 6470957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro-in vivo correlation and dissolution studies with oral theophylline dosage forms.
    el-Yazigi A; Sawchuk RJ
    J Pharm Sci; 1985 Feb; 74(2):161-4. PubMed ID: 3989685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the absorption from some commercial enteric-release theophylline products.
    Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo-in vitro correlations with sustained-release theophylline preparations.
    Ritschel WA; Koch HP; Alcorn GJ
    Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):609-18. PubMed ID: 6513678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zero-order release of theophylline from a core-in-cup tablet in sequenced simulated gastric and intestinal fluid.
    Danckwerts MP; van der Watt JG; Moodley I
    Drug Dev Ind Pharm; 1998 Feb; 24(2):163-7. PubMed ID: 15605446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.
    Horai Y; Ishizaki T; Sasaki T; Chiba K; Suganuma T; Echizen H; Ohnishi A
    Eur J Clin Pharmacol; 1983; 24(1):79-87. PubMed ID: 6832206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects.
    Osman MA; Patel RB; Irwin DS; Welling PG
    Biopharm Drug Dispos; 1983; 4(1):63-72. PubMed ID: 6839003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline.
    Emeje M; John-Africa L; Isimi Y; Kunle O; Ofoefule S
    Acta Pharm; 2012 Mar; 62(1):71-82. PubMed ID: 22472450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability studies of theophylline ethylcellulose microcapsules prepared by using ethylene-vinyl acetate copolymer as a coacervation-inducing agent.
    Lin SY; Yang JC
    J Pharm Sci; 1987 Mar; 76(3):219-23. PubMed ID: 3585738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theophylline controlled-release formulations: in vivo-in vitro correlations.
    Yu Z; Schwartz JB; Sugita ET
    Biopharm Drug Dispos; 1996 Apr; 17(3):259-72. PubMed ID: 8983400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.
    Hussein Z; Friedman M
    Pharm Res; 1990 Nov; 7(11):1167-71. PubMed ID: 2293217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pH on the in vitro dissolution and in vivo absorption of controlled-release theophylline in dogs.
    Vashi VI; Meyer MC
    J Pharm Sci; 1988 Sep; 77(9):760-4. PubMed ID: 3225770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution and bioavailability studies of whole and halved sustained-release theophylline tablets.
    Simons KJ; Frith EM; Simons FE
    J Pharm Sci; 1982 May; 71(5):505-11. PubMed ID: 7097493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dissolution profiles of theophylline extended-release dosage forms.
    Wolny D; Gruchlik A; Chodurek E; Szara M; Dzierzewicz Z
    Acta Pol Pharm; 2012; 69(6):1384-6. PubMed ID: 23285707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissolution of theophylline from sustained-release dosage forms and correlation with saliva bioavailability parameters.
    Chung BH; Shim CK
    J Pharm Sci; 1987 Oct; 76(10):784-7. PubMed ID: 3430341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Release, absorption and elimination of theophylline from fast and slowly released oral formulations].
    Frömming KH; Schwabe L; Staib AH; Rietbrock N; Lassmann A; Molz KH; Schuppan D; Siebert-Weigel M; Voegele D
    Arzneimittelforschung; 1983; 33(3):446-52. PubMed ID: 6683521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissolution of theophylline from film-coated slow release mini-tablets in various dissolution media.
    Fassihi AR; Munday DL
    J Pharm Pharmacol; 1989 Jun; 41(6):369-72. PubMed ID: 2570830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of stable isotope methodology in the evaluation of sustained-release theophylline dosage forms.
    Koup JR; Walker SB; Shapiro GG; Howald WN; Pierson WE; Bierman CW; Furukawa CT
    J Allergy Clin Immunol; 1986 Oct; 78(4 Pt 2):752-4. PubMed ID: 3771962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro dissolution behavior of some sustained-release theophylline dosage forms.
    Lin SY; Yang JC
    Pharm Acta Helv; 1989; 64(8):236-40. PubMed ID: 2780758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties of a new sustained-release theophylline preparation.
    Dahlqvist R; Billing B
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):69-72. PubMed ID: 6840927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.